Guidant's $96 mil. in charges will result in second quarter loss, firm says.
This article was originally published in The Gray Sheet
Executive Summary
GUIDANT'S SPEEDY AICD APPROVALS WILL COST $29 MIL. in charges to second quarter earnings, the company says. Guidant announced May 20 that it will take two non-recurring, non-cash charges totaling $96 mil. to second quarter 1996 (ends June 30) results: a $29 mil. charge to manufacturing costs as a result of the "obsolescence of older cardiac rhythm management (CRM) products and programmers," and a $69 mil. "impairment charge" for intangible assets "due to current sales trends" in the firm's Devices for Vascular Intervention (DVI) atherectomy business.
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.